174 related articles for article (PubMed ID: 32355298)
1. Polymorphisms in PARP1 predict disease-free survival of triple-negative breast cancer patients treated with anthracycline/taxane based adjuvant chemotherapy.
Liao Y; Liao Y; Li J; Xiong J; Fan Y
Sci Rep; 2020 Apr; 10(1):7349. PubMed ID: 32355298
[TBL] [Abstract][Full Text] [Related]
2. Genetic polymorphisms of autophagy-related gene 5 (ATG5) rs473543 predict different disease-free survivals of triple-negative breast cancer patients receiving anthracycline- and/or taxane-based adjuvant chemotherapy.
Li M; Ma F; Wang J; Li Q; Zhang P; Yuan P; Luo Y; Cai R; Fan Y; Chen S; Li Q; Xu B
Chin J Cancer; 2018 Jan; 37(1):4. PubMed ID: 29382381
[TBL] [Abstract][Full Text] [Related]
3. Significance of Tumor-Infiltrating Lymphocytes and the Expression of Topoisomerase IIα in the Prediction of the Clinical Outcome of Patients with Triple-Negative Breast Cancer after Taxane-Anthracycline-Based Neoadjuvant Chemotherapy.
Rao N; Qiu J; Wu J; Zeng H; Su F; Qiu K; Wu J; Yao H
Chemotherapy; 2017; 62(4):246-255. PubMed ID: 28472798
[TBL] [Abstract][Full Text] [Related]
4. Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto.
Loibl S; Weber KE; Timms KM; Elkin EP; Hahnen E; Fasching PA; Lederer B; Denkert C; Schneeweiss A; Braun S; Salat CT; Rezai M; Blohmer JU; Zahm DM; Jackisch C; Gerber B; Klare P; Kümmel S; Schem C; Paepke S; Schmutzler R; Rhiem K; Penn S; Reid J; Nekljudova V; Hartman AR; von Minckwitz G; Untch M
Ann Oncol; 2018 Dec; 29(12):2341-2347. PubMed ID: 30335131
[TBL] [Abstract][Full Text] [Related]
5. Polymorphisms in
Liao Y; Liao Y; Li J; Li J; Fan Y; Xu B
Cancer Manag Res; 2018; 10():3801-3808. PubMed ID: 30288111
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Pathologic Response Evaluation Systems after Anthracycline with/without Taxane-Based Neoadjuvant Chemotherapy among Different Subtypes of Breast Cancers.
Lee HJ; Park IA; Song IH; Kim SB; Jung KH; Ahn JH; Ahn SH; Kim HH; Gong G
PLoS One; 2015; 10(9):e0137885. PubMed ID: 26394326
[TBL] [Abstract][Full Text] [Related]
7. Major cardiovascular adverse events in older adults with early-stage triple-negative breast cancer treated with adjuvant taxane + anthracycline versus taxane-based chemotherapy regimens: A SEER-medicare study.
Roy S; Lakritz S; Schreiber AR; Kuna EM; Bradley CJ; Kondapalli L; Diamond JR
Eur J Cancer; 2024 Jan; 196():113426. PubMed ID: 38000217
[TBL] [Abstract][Full Text] [Related]
8. Classical CMF regimen as adjuvant chemotherapy for triple-negative breast cancer may be more effective compared with anthracycline or taxane-based regimens.
Wang S; Shi Y; Yuan Z; Wang X; Liu D; Peng R; Teng X; Qin T; Peng J; Lin G; Jiang X
Med Oncol; 2012 Jun; 29(2):547-53. PubMed ID: 21528408
[TBL] [Abstract][Full Text] [Related]
9. Taxane-based combinations as adjuvant chemotherapy for node-positive ER-positive breast cancer based on 2004-2009 data from the Breast Cancer Registry of the Japanese Breast Cancer Society.
Hojo T; Masuda N; Iwamoto T; Niikura N; Anan K; Aogi K; Ohnishi T; Yamauchi C; Yoshida M; Kinoshita T; Masuoka H; Sagara Y; Sakatani T; Kojima Y; Tsuda H; Kumamaru H; Miyata H; Nakamura S
Breast Cancer; 2020 Jan; 27(1):85-91. PubMed ID: 31327134
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcomes of adjuvant taxane plus anthracycline versus taxane-based chemotherapy regimens in older adults with node-positive, triple-negative breast cancer: A SEER-Medicare study.
Roy S; Lakritz S; Schreiber AR; Molina E; Kabos P; Wood M; Elias A; Kondapalli L; Bradley CJ; Diamond JR
Eur J Cancer; 2023 May; 185():69-82. PubMed ID: 36965330
[TBL] [Abstract][Full Text] [Related]
11. Capecitabine and cisplatin (XP) combination systemic chemotherapy in heavily pre-treated HER2 negative metastatic breast cancer.
Lee J; Kim HH; Ro SM; Yang JH
PLoS One; 2017; 12(2):e0171605. PubMed ID: 28234911
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant addition of capecitabine to early-stage triple-negative breast cancer patients receiving standard chemotherapy: a meta-analysis.
Li Y; Zhou Y; Mao F; Lin Y; Zhang X; Shen S; Sun Q
Breast Cancer Res Treat; 2020 Feb; 179(3):533-542. PubMed ID: 31865475
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of anthracycline/taxane-based neo-adjuvant chemotherapy on triple-negative breast cancer in BRCA1/BRCA2 mutation carriers.
Bignon L; Fricker JP; Nogues C; Mouret-Fourme E; Stoppa-Lyonnet D; Caron O; Lortholary A; Faivre L; Lasset C; Mari V; Gesta P; Gladieff L; Hamimi A; Petit T; Velten M
Breast J; 2018 May; 24(3):269-277. PubMed ID: 28929593
[TBL] [Abstract][Full Text] [Related]
14. NUP98 - a novel predictor of response to anthracycline-based chemotherapy in triple negative breast cancer.
Mullan PB; Bingham V; Haddock P; Irwin GW; Kay E; McQuaid S; Buckley NE
BMC Cancer; 2019 Apr; 19(1):236. PubMed ID: 30935371
[TBL] [Abstract][Full Text] [Related]
15. UCBG 2-04: Long-term results of the PACS 04 trial evaluating adjuvant epirubicin plus docetaxel in node-positive breast cancer and trastuzumab in the human epidermal growth factor receptor 2-positive subgroup.
D'Hondt V; Canon JL; Roca L; Levy C; Pierga JY; Le Du F; Campone M; Desmoulins I; Goncalves A; Debled M; Rios M; Ferrero JM; Serin D; Hardy-Bessard AC; Piot G; Brain E; Dohollou N; Orfeuvre H; Lemonnier J; Roché H; Delaloge S; Dalenc F
Eur J Cancer; 2019 Nov; 122():91-100. PubMed ID: 31634648
[TBL] [Abstract][Full Text] [Related]
16. BCL2 is an independent predictor of outcome in basal-like triple-negative breast cancers treated with adjuvant anthracycline-based chemotherapy.
Bouchalova K; Svoboda M; Kharaishvili G; Vrbkova J; Bouchal J; Trojanec R; Koudelakova V; Radova L; Cwiertka K; Hajduch M; Kolar Z
Tumour Biol; 2015 Jun; 36(6):4243-52. PubMed ID: 25616695
[TBL] [Abstract][Full Text] [Related]
17. Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with adjuvant doxorubicin and cyclophosphamide (SWOG S9313).
Sharma P; Barlow WE; Godwin AK; Pathak H; Isakova K; Williams D; Timms KM; Hartman AR; Wenstrup RJ; Linden HM; Tripathy D; Hortobagyi GN; Hayes DF
Ann Oncol; 2018 Mar; 29(3):654-660. PubMed ID: 29293876
[TBL] [Abstract][Full Text] [Related]
18. [Opportunity and challenge of neoadjuvant treatment in triple negative breast cancer].
Hao XP; Jiang ZF
Zhonghua Wai Ke Za Zhi; 2021 Feb; 59(2):101-103. PubMed ID: 33378800
[TBL] [Abstract][Full Text] [Related]
19. PITX2 DNA-methylation predicts response to anthracycline-based adjuvant chemotherapy in triple-negative breast cancer patients.
Absmaier M; Napieralski R; Schuster T; Aubele M; Walch A; Magdolen V; Dorn J; Gross E; Harbeck N; Noske A; Kiechle M; Schmitt M
Int J Oncol; 2018 Mar; 52(3):755-767. PubMed ID: 29328369
[TBL] [Abstract][Full Text] [Related]
20. Impact of platinum-based chemotherapy on the prognosis of early triple-negative breast cancer: a systematic review and meta-analysis.
Zhao F; Shen G; Dong Q; Xin Y; Huo X; Wang M; Liu Z; Zhao Y; Ren D; Xie Q; Liu Z; Li Z; Gao L; Du F; Zhao J
Clin Exp Med; 2023 Oct; 23(6):2025-2040. PubMed ID: 36422737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]